International Workshop on CLL, October 6-9 in Boston

[Katie-LMHC-Artist]

Some of the abstracts may be of interest. Here is a link. CLL specialists attending from all over the world. Others are fighting hard on our behalf!!!

iwcll2023.org/

iwcll2023.org/wp-content/up...

[Katie-LMHC-Artist]

I looked at the program. Each topic has 15 minutes. My guess is that they highlight what is in the research and the participants can then have the option to read the research. My CLL specialist is part of the program!

[CLLerinOz Administrator Volunteer]

Updates from the iwCLL 2023 conference can be found on Onclive at onclive.com/conference/inte...

At present, there are articles and videos covering the following topics:

"Matching-Adjusted Analysis Shows Acalabrutinib/Obinutuzumab Offers PFS Benefit Vs Zanubrutinib in CLL/SLL Without 17p Deletions

Dr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLL

Dr Coombs on Switching to Treatment With a BCL-2 Inhibitor Vs a Covalent BTK Inhibitor in CLL/SLL

Acalabrutinib Is Associated With Low Frequency of Cardiac Events Across 3 Randomized Trials in CLL

Venetoclax Elicits Responses in B-Cell Receptor–Pretreated CLL Regardless of Mutation Status

Continued Maintenance With Obinutuzumab Plus Acalabrutinib/Venetoclax Boosts uMRD Rate in R/R CLL

Epcoritamab Monotherapy Demonstrates High Response Rates in High-Risk Relapsed/Refractory CLL

Pirtobrutinib Maintains Efficacy and Decreases BTK C481 Clones Despite Acquired Resistance Mutations in CLL

Venetoclax and Rituximab Combination Maintains Survival Benefit in Relapsed/Refractory CLL

Dr Danilov on the Investigation of BTK Degraders in CLL

Dr Woyach on the Prevalence of Mutations in Previously Treated Patients With CLL

Retrospective Analysis Sheds Light on Mutations Linked With BTK Inhibitor Resistance in CLL

Dr Melenhorst on the Evolving Understanding of CAR T-Cell Therapies in CLL

Dr Shadman on Zanubrutinib in CLL/SLL Intolerant to Prior BTK Inhibitors

MRD Could Guide Venetoclax/Ibrutinib Duration in Previously Untreated, Intermediate-Risk CLL

Ibrutinib Cessation Following Prolonged Exposure Supports Intermittent Investigation in CLL"

Those of you who are still on Twitter/X, can also find updates from the conference, including screen shots of some presentation slides using the hashtag #iwcll2023

CLLerinOz

[Katie-LMHC-Artist in reply to CLLerinOz]

Lots of information! Thank you!😊

[CLLerinOz Administrator Volunteer]

For those looking for more details about any of the abstracts from this conference, the iwCLL website explains that "Full abstracts will be published in Leukemia and Lymphoma in the online journal."

To access them, open the following link and then select 'View PDF'. See attached image which shows where you'll find that option.

tandfonline.com/doi/abs/10....

CLLerinOz

iwCLL 2023 abstracts are available online

[Katie-LMHC-Artist]

👍 Thank you!

[CLLerinOz Administrator Volunteer]

VJHemOnc has recently uploaded a series of short videos covering some of the topics covered at the iwCLL 2023 conference.

vjhemonc.com/event/iwcll-20...

These videos, which are usually only a few minutes long, are presented by CLL specialists and intended for healthcare professionals. Currently, there are videos on the following topics:

"Future research priorities and unmet needs in patients with CLL

Optimising initial therapy of CLL

Associated toxicities of novel therapies for CLL

Sequencing of therapies in patients with R/R CLL

The use of surrogate endpoints in CLL clinical trials

Evaluating surrogate endpoints in CLL clinical trials

Optimizing initial therapy in CLL: time-limited, all oral approaches

Real-world safety and efficacy of first- and second- generation BTK inhibitors in CLL

MAIC of pirtobrutinib vs venetoclax continuous monotherapy for R/R CLL

Monitoring infection risk in patients with CLL and insights into the Pre-Vent ACaLL trial

EPCORE CLL-1: Epcoritamab in patients with R/R CLL and Richter's transformation

The current role of continuous BTK inhibitors in CLL treatment: benefits and drawbacks

Integrating MRD data into treatment decisions in CLL

Matching-adjusted indirect comparisons of ELEVATE-TN versus SEQUOIA

Challenges with defining fitness in CLL & important co-morbidities to consider when selecting therapies

Choosing between continuous versus fixed-duration therapy in CLL"

VJHemOnc also shares its videos on its YouTube channel. youtube.com/@Vjhemonc

CLLerinOz